Category: Patients

Announcing our Educational Booklet Series!
Quality and reliable information has always been a focus of the Amyloidosis Research Consortium (ARC). When patients are first diagnosed, it’s hard to know where to turn to learn about your options and what may lie ahead. (more…)
Read More
HTA Toolkit for Patient organizations
ARC Launches HTA Toolkit for Patient Advocates
ARC has published a Health Technology Assessment Toolkit to equip patients and patient groups within Europe, as well as globally, with the tools to advocate on behalf of themselves and other patients for access to new treatments. (more…)
Read More
ARC Developing a Disease-Specific PRO Tool for Patients with ATTR Amyloidosis
ARC is developing a patient-reported outcome (PRO) measurement tool in ATTR amyloidosis to be used to understand and measure the impact of the disease on patients from the patient’s perspective. (more…)
Read More
The Amyloidosis Forum – bringing together the AL amyloidosis community with FDA
ARC is excited to announce the inaugural gathering of The Amyloidosis Forum on November 12, 2019 at FDA’s White Oak Campus in Silver Spring, MD. (more…)
Read More
Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) approved by FDA
This represents the first FDA approved treatment in ATTR-CM for both the wild-type and hereditary forms of ATTR amyloidosis. (more…)
Read More

AMYLOIDOSIS RESEARCH CONSORTIUM, INC.
320 Nevada Street, Suite 210 Newton, MA 02460 USA | 617-467-5170
arc@arci.org

ARC is a 501(c)(3) nonprofit organization